Table 3.

Relative risk of novel doublet and triplet combinations in relapsed MM

CombinationHR for PFSPFS (mo)≥VGPR, %≥CR, %Remarks
Elotuzumab-Rd vs Rd 0.71 19 35 5 Effective after 2-3 lines of therapy 
Carfilzomib-Rd vs Rd 0.69 26.3 38 32 Effective after 1 line 
Daratumumab-Rd vs Rd 0.37 NR at 18 mo 76 43 Most effective in high-risk cytogenetics 
Ixazomib-Rd vs Rd 0.82 20.6 48 32 Effective after 2−3 lines 
Daratumumab-Vd vs Vd 0.39 NR at 12 mo 28 10 More effective than carfilzomib-dexamethasone 
Panobinostat-Vd vs Vd 0.63 12 28 11 Available for ≥3 lines 
Carfilzomib-d vs bortezomib-d 0.53 18.3 54 13 More affordable, less toxic 
CombinationHR for PFSPFS (mo)≥VGPR, %≥CR, %Remarks
Elotuzumab-Rd vs Rd 0.71 19 35 5 Effective after 2-3 lines of therapy 
Carfilzomib-Rd vs Rd 0.69 26.3 38 32 Effective after 1 line 
Daratumumab-Rd vs Rd 0.37 NR at 18 mo 76 43 Most effective in high-risk cytogenetics 
Ixazomib-Rd vs Rd 0.82 20.6 48 32 Effective after 2−3 lines 
Daratumumab-Vd vs Vd 0.39 NR at 12 mo 28 10 More effective than carfilzomib-dexamethasone 
Panobinostat-Vd vs Vd 0.63 12 28 11 Available for ≥3 lines 
Carfilzomib-d vs bortezomib-d 0.53 18.3 54 13 More affordable, less toxic 

d, dexamethasone; NR, not reached.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal